J Med Virol. 2022 May 10. doi: 10.1002/jmv.27848. Online ahead of print.
ABSTRACT
BACKGROUND: This study evaluated the optimal timing of a primary three-dose hepatitis B vaccination and post-vaccination serologic testing (PVST) among a large group of healthy naïve adults in the Netherlands.
METHODS: Data were collected from the Ease Travel Clinic hepatitis B vaccination database.
RESULTS: The study population consisted of 22,997 adults who received three hepatitis B vaccinations. Seroprotection was attained in 97.3% individuals. When compared to PVST performed at 1-2 months (98.2%) after the final dose, lower seroprotection rates were observed with <1 (97.3%, p=0.128), 3 – 6 (90.6%, p<0.001) and >7 (88.4%, p<0.001) months after vaccination. Among the subpopulation with a PVST 1-2 months, no statistically significant difference was observed for the various intervals between 1st and 2nd vaccination (<1, 1-2, 3-4 or >5 months). When compared to 4-5 months between 2nd and 3rd vaccine dose, lower seroprotection rates were observed with <4 (OR: 0.29, p = 0.020) and >12 (OR: 0.22, p < 0.001) months, though comparable rates were observed with 6-11 months interval (OR: 0.85, p = 0.262).
CONCLUSIONS: Our data indicate that PVST should be obtained 1-2 months after the last vaccination and a delayed PVST was the major determinant of a lower seroprotection rate after primary three dose hepatitis B vaccination schedule. Based on our data, the hepatitis B vaccination also leaves room for flexibility for the second dose and the third dose without the necessity of restarting the vaccination series or confirmation of the immune response to the vaccine. This article is protected by copyright. All rights reserved.
PMID:35538595 | DOI:10.1002/jmv.27848
